Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 140
Filtrar
2.
Int J Mol Sci ; 22(21)2021 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-34769429

RESUMO

(1) Background: Artemia salina is a brine shrimp containing high concentrations of dinucleotides, molecules with properties for dry eye treatment. For this reason, the purpose of the study was to evaluate the effect of the artificial tears based on an extract of Artemia salina in a rabbit dry eye model. (2) Methods: A prospective and randomized study was carried out. Twenty rabbits were divided into 4 groups (n = 5, each group): healthy rabbits, dry eye rabbits, dry eye rabbits treated with hypromellose (HPMC), and dry eye rabbits treated with Artemia salina. Dry eye was induced by the topical instillation of 0.2% benzalkonium chloride. The measurements were performed before and after the treatment for 5 consecutive days. (3) Results: The topical instillation of artificial tears containing Artemia salina showed beneficial effects on tear secretion, tear break-up time, corneal staining, the density of Goblet cells, heigh of mucin cloud secreted by these cells, and mRNA levels of IL-1ß and MMP9 in conjunctival cells. Compared with the HPMC, there was a statistically significant improvement (p < 0.05) with the Artemia salina in all the variables under study, except for the conjunctival hyperemia, density of Goblet cells, and mRNA levels of IL-6. (4) Conclusions: The potential of artificial tears based on Artemia salina as a secretagogue agent for dry eye treatment was confirmed, opening the door for future clinical trials and studies to extrapolate the findings for dry eye patients.


Assuntos
Artemia/química , Fosfatos de Dinucleosídeos/farmacologia , Síndromes do Olho Seco/tratamento farmacológico , Derivados da Hipromelose/farmacologia , Lubrificantes Oftálmicos/administração & dosagem , Extratos Vegetais/farmacologia , Lágrimas/efeitos dos fármacos , Animais , Modelos Animais de Doenças , Síndromes do Olho Seco/metabolismo , Masculino , Coelhos , Lágrimas/metabolismo
3.
Dtsch Med Wochenschr ; 146(20): 1344-1351, 2021 10.
Artigo em Alemão | MEDLINE | ID: mdl-34644795

RESUMO

BACKGROUND: Graves' orbitopathy (GO) is an autoimmune orbital disease which is mostly associated with Graves' disease and requires good interdisciplinary cooperation. To minimize irreversible damages a stage-adapted anti-inflammatory therapy is of great importance. MATERIAL AND METHODS: Discussion of the latest results of new findings of the pathogenesis, randomized controlled trials on anti-inflammatory treatments for Graves' orbitopathy and novel therapeutic concepts. RESULTS: In all patients with GO achieving euthyroidism, as well as cessation of smoking is very important to avoid prolongated diseases. Mild cases of GO can be treated with selenium supplementation and artificial tears. The moderate-to-severe, active form of GO requires primarily i. v. steroids in combination with orbital irradiation in case of impaired motility. In patients with insufficient therapeutic response after 6 weeks, treatment should be switched to other immunosuppressive agents. In severe sight-threatening cases even high-dose i. v. steroid treatments are often ineffective and bony orbital decompression is necessary. As latest research data have improved our understanding of the pathophysiology of GO, targeted therapies have been developed for GO. Teprotumumab, an IGF-1 receptor antibody, was shown effective in treating GO patients in a phase III trial and should soon be awarded approval for Europe. Inactive patients, who suffer from disturbing exophthalmos should be also treated with bony decompression before eye muscle or lid surgery. CONCLUSION: The current concept for Graves' orbitopathy is as follows: first anti-inflammatory therapy then surgical correction of the permanent defects. This might be modified in the future, due to the promising effects of targeted therapies.


Assuntos
Oftalmopatia de Graves/terapia , Administração Intravenosa , Anticorpos Monoclonais Humanizados/uso terapêutico , Antioxidantes/administração & dosagem , Descompressão Cirúrgica , Oftalmopatia de Graves/diagnóstico , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Órbita/efeitos da radiação , Receptor IGF Tipo 1/imunologia , Fatores de Risco , Selênio/administração & dosagem , Abandono do Hábito de Fumar , Esteroides/administração & dosagem
4.
Cornea ; 40(10): 1336-1339, 2021 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-34481410

RESUMO

PURPOSE: The purpose of this study was to evaluate whether tear film stability worsens with the use of masks in patients with dry eye disease, objectively analyzing the tear film stability using noninvasive tear film breakup time (NITBUT) with and without a face mask. METHODS: A cross-sectional study including patients with moderate or severe dry eye disease was conducted. Tear stability was measured using an Oculus Keratograph 5M (Oculus, Wetzlar, Germany), which records NITBUT, both first and average NITBUT. Two measurements were taken: an initial measurement with a mask and a second measurement after 10 minutes without wearing the face mask. RESULTS: Thirty-one patients were included with a mean age of 57.6 ± 11.7 years (range 31-80) and 30 being female (97%). Mean first NITBUT with face mask was 6.2 ± 3.8 seconds (range 2.0-19.8), which increased to 7.8 ± 5.6 seconds (range 2.3-24.0) without the use of mask (P = 0.029), differences being -1.6 ± 0.7 seconds (CI 95% -3.1075 to -0.1770). Mean average NITBUT with a face mask was 12.3 ± 4.8 seconds (range 4.0-19.4) and increased to 13.8 ± 5 seconds (range 5.5-24.0) without the use of mask (P = 0.006), mean difference being -1.5 ± 0.5 seconds (CI 95% -2.5290 to -0.4458). CONCLUSIONS: Face mask use decreases tear film stability in patients with moderate-to-severe dry eye.


Assuntos
Síndromes do Olho Seco/fisiopatologia , Máscaras , Lágrimas/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos Transversais , Ciclosporina/administração & dosagem , Síndromes do Olho Seco/tratamento farmacológico , Feminino , Humanos , Imunossupressores/administração & dosagem , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Pessoa de Meia-Idade , Microscopia com Lâmpada de Fenda , Acuidade Visual/fisiologia
5.
Medwave ; 21(5): e8213, 2021 Jun 22.
Artigo em Espanhol, Inglês | MEDLINE | ID: mdl-34214069

RESUMO

INTRODUCTION: Dry eye is one of the most common ocular surface disorders. Although artificial tear drops therapy is the most widely used treatment, it has recently been suggested that autologous serum could be a beneficial alternative treatment for this disorder, but its use is controversial. METHODS: We searched in Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE/PubMed, EMBASE, Cochrane, among others. We extracted data from the systematic reviews, reanalyzed data of primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. RESULTS AND CONCLUSIONS: We identified six systematic reviews, including seven primary studies overall, of which all were randomized trials. We concluded that autologous serum treatment might not lead to adverse effects compared to artificial teardrops, but the certainty of the evidence is low. On the other hand, we are uncertain whether autologous serum therapy improves the quality of life, severity of the pathology, pain or the corneal epitheliopathy grade compared to artificial tear drops as the certainty of the evidence has been assessed as very low.


INTRODUCCIÓN: El ojo seco es una de las patologías oculares más frecuentes. Si bien el tratamiento más utilizado es el uso de lágrimas artificiales, se ha planteado el uso de suero autólogo como una alternativa terapéutica beneficiosa para pacientes con esta condición. Sin embargo, su uso es controvertido. MÉTODOS: Realizamos una búsqueda en Epistemonikos, la mayor base de datos de revisiones sistemáticas en salud, la cual es mantenida mediante el cribado de múltiples fuentes de información, incluyendo MEDLINE/PubMed, EMBASE, Cochrane, entre otras. Extrajimos los datos desde las revisiones identificadas, analizamos los datos de los estudios primarios, realizamos un metanálisis y preparamos una tabla de resumen de los resultados utilizando el método Grading of Recommendations Assessment, Development and Evaluation, GRADE. RESULTADOS Y CONCLUSIONES: Identificamos seis revisiones sistemáticas que en conjunto incluyeron siete estudios primarios, de los cuales, todos corresponden a ensayos aleatorizados. Concluimos que el uso de suero autólogo podría no presentar efectos adversos asociados a su uso, pero la certeza de la evidencia es baja. Por otro lado, no es posible establecer con claridad si el uso de suero autólogo tiene un efecto sobre la mejora de la calidad de vida, severidad del ojo seco, dolor o grado de epiteliopatía corneal debido a que la certeza de la evidencia existente ha sido evaluada como muy baja.


Assuntos
Síndromes do Olho Seco/terapia , Lubrificantes Oftálmicos/administração & dosagem , Soluções Oftálmicas/uso terapêutico , Bases de Dados Factuais , Humanos , Dor , Qualidade de Vida , Soro , Cloreto de Sódio/uso terapêutico , Revisões Sistemáticas como Assunto , Resultado do Tratamento
6.
Optom Vis Sci ; 98(5): 469-475, 2021 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-33973917

RESUMO

SIGNIFICANCE: The effectiveness of masking is rarely evaluated or reported in single- or double-masked clinical trials. Knowledge of treatment assignment by participants and clinicians can bias the assessment of treatment efficacy. PURPOSE: This study aimed to evaluate the effectiveness of masking in a double-masked trial of 5% povidone-iodine for the treatment of adenoviral conjunctivitis. METHODS: The Reducing Adenoviral Patient Infected Days study is a double-masked, randomized trial comparing a one-time, in-office administration of 5% povidone-iodine with artificial tears for the treatment of adenoviral conjunctivitis. Masking was assessed by asking participants and masked clinicians at designated time points if they believed the treatment administered was povidone-iodine or artificial tears, or if they were unsure. Adequacy of masking was quantified using a modified Bang Blinding Index. RESULTS: Immediately after treatment, 34% of participants who received povidone-iodine and 69% of those who received artificial tears guessed incorrectly or were unsure of their treatment (modified Bang Indices of 0.31 and -0.38, respectively). On day 4, 38% of the povidone-iodine participants and 52% of the artificial tear participants guessed incorrectly or were unsure of their treatment (modified Bang Indices of 0.24 and -0.05, respectively), indicating adequate and ideal masking. On days 1, 4, 7, 14, and 21, masked clinicians guessed incorrectly or were unsure of treatment in 53%, 50%, 40%, 39%, and 42% among povidone-iodine participants compared with 44%, 35%, 38%, 35%, and 39% among artificial tears participants, respectively. The modified Bang Indices for clinician masking in the povidone-iodine group ranged from -0.05 to 0.25 and from 0.13 to 0.29 in the artificial tears group. CONCLUSIONS: Masking of participants and clinicians was adequate. Successful masking increases confidence that subjective measurements are not biased. We recommend quantitative assessment and reporting the effectiveness of masking in ophthalmic clinical trials.


Assuntos
Infecções por Adenovirus Humanos/tratamento farmacológico , Anti-Infecciosos Locais/uso terapêutico , Conjuntivite Viral/tratamento farmacológico , Infecções Oculares Virais/tratamento farmacológico , Povidona-Iodo/uso terapêutico , Administração Oftálmica , Adolescente , Adulto , Método Duplo-Cego , Feminino , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Soluções Oftálmicas , Projetos Piloto , Resultado do Tratamento , Adulto Jovem
7.
Optom Vis Sci ; 98(4): 334-340, 2021 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-33828043

RESUMO

SIGNIFICANCE: The prevalence of dry eye disease and low vision increases with age; they share risk factors and can be the result of underlying common causes. They are generally studied separately; however, combining these perspectives is relevant for research on assistive technology given that sustained focus affects the tear film because of decreased blinking rates. PURPOSE: The objective of this study was to elucidate to which extent dry eye disease risk factors, signs, and symptoms are assessed in low vision patients who receive an eye examination as part of their vision rehabilitation services. METHODS: Using a retrospective chart review, dry eye disease risk factors, signs, or symptoms were extracted from 201 randomly selected files that contained an eye examination in the past 5 years from two vision rehabilitation centers. RESULTS: Demographic variables of charts from the two sites did not differ (mean visual acuity, 0.85 logMAR [standard deviation, 0.53; range, 0 to 2.3]; mean age, 71.2 years [standard deviation, 19 years; range, 24 to 101 years]). Fifty charts (25%) mentioned at least one dry eye disease symptom. Sixty-one charts (30.3%) reported systemic medications that can exacerbate dry eye disease, whereas 99 (49.2%) contained at least one systemic disease thought to contribute to dry eye disease symptoms; 145 (72.1%) mentioned at least one type of ocular surgery. Artificial tears were documented in 74 charts (36.8%). Few specific dry eye tests were performed, with the exception of corneal integrity assessment reported in 18 charts (8.95%). CONCLUSIONS: Low vision patients have multiple risk factors for dry eye disease; however, dry eye disease tests were not frequently performed in comprehensive low vision eye examinations in this sample. More efforts should be made to assess dry eye disease to enhance comfort and functional vision, especially with the increasing demands of digital devices as visual aids.


Assuntos
Síndromes do Olho Seco/diagnóstico , Baixa Visão/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Síndromes do Olho Seco/tratamento farmacológico , Síndromes do Olho Seco/fisiopatologia , Feminino , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Risco , Lágrimas/fisiologia , Baixa Visão/fisiopatologia , Acuidade Visual/fisiologia , Adulto Jovem
8.
Int J Biol Macromol ; 176: 47-65, 2021 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-33581206

RESUMO

Most of the people in the world are affected by glaucoma, which leads to irreversible blindness. Several patient friendly treatments are available, nevertheless medications lack an easy and efficient way of sustained delivery. To make the delivery with enhanced bioavailability, biodegradable and non-biodegradable polymers-based drug carriers are explored. However, ocular drug delivery issues have not been resolved yet due to less adhesiveness, poor penetration ability, pH, and temperature dependent burst releases. Chitosan is found to be effective for ocular drug delivery due to excellent physio-chemical properties in terms of overcoming the existing issues. In this review, we aim to highlight why it has been chosen and the holy grail for ocular drug delivery. Besides, we have comprehensively reviewed recent patents on chitosan as a platform for ocular drug delivery and future perspectives on factors, lacunae and challenges that need to be addressed for better ocular delivery methods for glaucoma management.


Assuntos
Quitosana/química , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos , Glaucoma/tratamento farmacológico , Administração Oftálmica , Materiais Biocompatíveis/química , Materiais Biocompatíveis/metabolismo , Quitosana/metabolismo , Lentes de Contato , Lesões da Córnea/tratamento farmacológico , Portadores de Fármacos/metabolismo , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Lubrificantes Oftálmicos/química , Teste de Materiais , Microscopia Eletrônica de Varredura , Muramidase/metabolismo , Nanopartículas/química , Nanopartículas/metabolismo , Nanopartículas/ultraestrutura , Agentes Molhantes/administração & dosagem , Agentes Molhantes/química , Cicatrização/efeitos dos fármacos
9.
Curr Eye Res ; 46(2): 195-201, 2021 02.
Artigo em Inglês | MEDLINE | ID: mdl-32602744

RESUMO

PURPOSE: To determine the clinical benefits of Meibomian gland expression therapy for the treatment of dry-eye disease caused by Meibomian gland dysfunction (MGD). METHODS: In a prospective randomized controlled double-masked trial, 87 eyes of 44 patients with MGD and dry-eye symptoms were enrolled. Patients were randomly assigned into two groups; a study group that received therapeutic Meibomian gland expression once every month, and a control group that received sham treatment. All patients received treatment with artificial tears. RESULTS: One week after the first treatment, the Ocular Surface Disease Index (OSDI) score improved significantly in the study group (mean change -18.5 ± 21.2, p = .01) but not in the control group (-3.8 ± 15.8, p = .16); after 1 month, both groups improved significantly (-20.5 ± 19 p = .001 in the study group and -6.5 ± 11, p = .016 in the control group). The improvement continued at 2 months in the study group (-28.4 ± 26.1, P < .0001) and in the control group (-9.6 ± 9.9, p = .007). The blepharitis questionnaire score improved in the study group compared to controls after 1 week (-9.95 ± 12.52 versus -1.77 ± 9.1, p = .03) 1 month (-11.5 ± 10.9 versus -1.1 ± 9.4, p = .02) and 2 months (-16.5 ± 8.0 versus -8.8 ± 11.7, p = .02). Burning sensation was significantly reduced only in the study group. Mean change after 2-month treatment was -2.00 ± 1.2583 (p < .0001) vs -0.67 ± 1.44 (p = .08). The trend was similar in Eyelid scales. Conjunctival hyperemia improved only in the study group 1 week after the treatment (-0.12 ± 0.32 p = .03). CONCLUSION: Therapeutic Meibomian gland expression improves dry-eye symptoms in subjects with MGD, compared to conventional treatment with artificial tears.


Assuntos
Síndromes do Olho Seco/terapia , Lubrificantes Oftálmicos/administração & dosagem , Disfunção da Glândula Tarsal/terapia , Glândulas Tarsais/metabolismo , Fototerapia/métodos , Lágrimas/metabolismo , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Método Duplo-Cego , Síndromes do Olho Seco/etiologia , Síndromes do Olho Seco/metabolismo , Feminino , Seguimentos , Humanos , Masculino , Disfunção da Glândula Tarsal/complicações , Disfunção da Glândula Tarsal/metabolismo , Glândulas Tarsais/diagnóstico por imagem , Pessoa de Meia-Idade , Estudos Prospectivos , Inquéritos e Questionários , Adulto Jovem
10.
Am J Ophthalmol ; 221: 1-8, 2021 01.
Artigo em Inglês | MEDLINE | ID: mdl-32828877

RESUMO

PURPOSE: To assess the influence of artificial tears of different viscosity on K-readings prior to cataract surgery. DESIGN: Prospective randomized crossover, before-and-after clinical study. METHODS: Setting: Department of Ophthalmology, Medical University of Vienna. PATIENT POPULATION: A total of 123 eyes of 80 patients prior to cataract surgery were assigned to 2 groups based on normal and dry eyes. INTERVENTION: Two native baseline keratometries were followed by instillation of either high- or low-viscosity eye drops. Keratometry was repeated 30 seconds, 2 minutes, and 5 minutes after instillation. MAIN OUTCOME MEASURES: Influence of eye drops of different viscosity in normal and dry eyes on short time K-readings. RESULTS: Repeatability between native baseline measurements was high (standard deviation = 0.02 mm in normal and in dry eyes). In normal and dry eyes, a statistically significant increase in measurement variability after instillation of both low-viscosity and high-viscosity eye drops was observed (P < .01). Measurement variability was most pronounced between baseline measurement and 30 seconds and diminished over time. Variability of K-readings appeared higher in dry eyes compared with normal eyes. Astigmatism changed more than 0.5 diopters in 13.2% of normal eyes and 34.4% in dry eyes using eye drops of high viscosity. CONCLUSION: Tear film-stabilizing eye drops prior to keratometry measurements influenced K-readings significantly, especially in dry eyes. A time period of more than 5 minutes should be allowed to pass after instillation of eye drops. The higher the viscosity of the eye drops, the stronger the influence and the longer its persistence.


Assuntos
Catarata/complicações , Córnea/patologia , Técnicas de Diagnóstico Oftalmológico/instrumentação , Síndromes do Olho Seco/tratamento farmacológico , Lubrificantes Oftálmicos/administração & dosagem , Administração Oftálmica , Idoso , Idoso de 80 Anos ou mais , Astigmatismo/fisiopatologia , Biometria/instrumentação , Estudos Cross-Over , Síndromes do Olho Seco/fisiopatologia , Feminino , Humanos , Lubrificantes Oftálmicos/química , Masculino , Pessoa de Meia-Idade , Soluções Oftálmicas , Facoemulsificação , Estudos Prospectivos , Reprodutibilidade dos Testes , Viscosidade
12.
Cornea ; 40(2): 228-231, 2021 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-33201057

RESUMO

PURPOSE: This study aimed to present the efficacy and safety of cenegermin eye drop (Oxervate; Dompè Farmaceutici, Milan, Italy) treatment in a pediatric patient affected by neurotrophic keratopathy (NK) with Goldenhar syndrome. METHODS: This case reports an infant presenting ulceration and a small central opacity in the cornea of the right and left eyes, respectively. The NK bilaterally worsened despite the use of therapeutic contact lenses and temporary partial tarsorrhaphy. Magnetic resonance imaging showed absence and hypoplasia of the right and left trigeminal nerves, respectively. Cenegermin eye drops were administered 1 drop/each eye, 6 times daily for 8 weeks to promote corneal healing. RESULTS: Complete healing was achieved in both eyes after treatment. During the 16-month follow-up period, no epithelial defect, recurrence, or complications were noticed, whereas corneal opacities progressively became clearer, although insignificant improvements in corneal sensitivity or in the reflex tearing were observed. CONCLUSIONS: Cenegermin was effective in treating NK in an infant with Goldenhar syndrome.


Assuntos
Córnea/inervação , Opacidade da Córnea/tratamento farmacológico , Úlcera da Córnea/tratamento farmacológico , Fator de Crescimento Neural/administração & dosagem , Insensibilidade Congênita à Dor/complicações , Doenças do Nervo Trigêmeo/tratamento farmacológico , Nervo Trigêmeo/anormalidades , Administração Oftálmica , Opacidade da Córnea/congênito , Opacidade da Córnea/diagnóstico por imagem , Úlcera da Córnea/congênito , Úlcera da Córnea/diagnóstico por imagem , Seguimentos , Humanos , Lactente , Lubrificantes Oftálmicos/administração & dosagem , Imageamento por Ressonância Magnética , Masculino , Soluções Oftálmicas/administração & dosagem , Proteínas Recombinantes/administração & dosagem , Doenças do Nervo Trigêmeo/congênito , Doenças do Nervo Trigêmeo/diagnóstico por imagem , Cicatrização/efeitos dos fármacos
13.
Cutan Ocul Toxicol ; 40(1): 14-20, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33342322

RESUMO

AIM: To evaluate the short-term effect of 0.15% sodium hyaluronate (SH), 0.20% SH, and Trehalose + 0.15% SH on anterior corneal aberrations in dry eye patients. METHODS: 76 eyes of 76 dry eye patients were divided into three groups. Non-preserved 1.5 mg/mL SH was administered in group 1, non-preserved 2.0 mg/mL SH was administered in group 2, and non-preserved trehalose 30 mg/mL and 1.5 mg/mL SH was administered in group 3. Aberrometry measurements were performed before and 10 min after application of the artificial tear drop. Using the Pentacam Scheimpflug imaging system, total root mean square (RMS), lower-order aberration (LOA), higher-order aberrations (HOAs), spherical aberration (SA), trefoil, and coma aberrations were investigated. RESULTS: In each group; the RMS of total, LOA, HOAs, and spherical aberration were significantly decreased after the artificial drop instillation, compared with those of them at baseline; and in groups 1 and 2, vertical trefoil term was also significantly increased, compared with those of them at baseline. According to intergroup analyzes, there was no significant outcome. CONCLUSIONS: It was observed that three artificial tears reduced the anterior corneal aberrations, in a 10-min period. The short-term effect of three artificial tears on the anterior corneal aberration was similar.


Assuntos
Síndromes do Olho Seco/tratamento farmacológico , Ácido Hialurônico/administração & dosagem , Lubrificantes Oftálmicos/administração & dosagem , Trealose/administração & dosagem , Aberrometria , Adulto , Idoso , Córnea/diagnóstico por imagem , Córnea/efeitos dos fármacos , Síndromes do Olho Seco/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Adulto Jovem
14.
Optom Vis Sci ; 97(12): 1070-1079, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33259378

RESUMO

SIGNIFICANCE: Digital display use has been accepted as a contributing factor to dry eye disease. Nowadays, plenty of new models of digital displays have been developed, and the differences in their nature and the ways in which they are set and used may contribute to differences in the eye-related problems they cause. PURPOSE: This study aimed to analyze the differences in ocular surface, tear film, and visual fatigue parameters after reading on different digital displays, with and without initial instillation of artificial tears. METHODS: Thirty-one healthy individuals ranging in age from 20 to 26 years (mean ± standard deviation, 21.26 ± 1.73 years) were included in this prospective clinical study. Subjects' ocular surface, tear film, and visual fatigue parameters were assessed after reading for 15 minutes on a laptop computer, tablet, e-reader, and smartphone with matching characteristics and a baseline measurement. Measurements were taken with and without the instillation of artificial tears before the reading tasks and included the Ocular Surface Disease Index questionnaire, the Computer Vision Syndrome Questionnaire, tear meniscus height, the Schirmer I test, noninvasive keratograph break-up time, osmolarity, bulbar redness, and pupil size. RESULTS: Statistically significant differences in the Ocular Surface Disease Index, Computer Vision the Syndrome Questionnaire, tear meniscus height, the Schirmer I test, noninvasive keratograph break-up time, osmolarity, and bulbar redness were obtained when comparing the displays (P < .05). Best results were obtained with the smartphone and the e-reader. Conversely, the computer produced the highest disturbance on the ocular surface and tear film. Finally, the instillation of artificial tears revealed no statistical improvement of ocular surface or tear film parameters for the same device (P > .05). CONCLUSIONS: Taking into account the clinical tests for dry eye diagnosis, the smartphone may be considered as the least disturbing display, producing lower dry eye signs and symptoms in comparison with other devices.


Assuntos
Astenopia/fisiopatologia , Computadores de Mão , Síndromes do Olho Seco/fisiopatologia , Leitura , Lágrimas/fisiologia , Adulto , Feminino , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Concentração Osmolar , Estudos Prospectivos , Inquéritos e Questionários , Adulto Jovem
15.
J Ocul Pharmacol Ther ; 36(10): 725-731, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-33180002

RESUMO

Purpose: High-frequency applied cetalkonium chloride (CAC) and benzalkonium chloride (BAC) 0.02% did not hamper corneal healing in a living rabbit model of induced corneal erosion. In contrast, the ex vivo eye irritation test (EVEIT) shows inhibition of healing for these substances. In a systematic ex vivo reproduction of the in vivo experiments, we discuss the background of these differences. Methods: Excised rabbit corneas (n = 5 per group) were cultured in artificial anterior chambers (EVEIT). Four erosions were induced for each cornea before starting regular 21 installations/day over 3 days of (1) CAC containing eye drops (Cationorm®), (2) 0.02% BAC. Corneal fluorescein staining, quantification of glucose-/lactate consumption, and histology were performed. Results: BAC 0.02% treated corneas showed increased epithelial lesions from 10.13 ± 0.65 mm2 to 10 ± 0.8 mm2 on day 0, to 86.82 ± 5.18 mm2 (P < 0.0001) by day 3. After a trend toward smaller lesions for CAC on day 1, erosion sizes increased significantly by day 3 from 9.82 ± 0.30 mm2 to 29.51 ± 16.87 mm2 (P < 0.05). For 1 cornea, corneal erosions nearly disappeared on day 3 (0.89 mm2). Corneal lactate increased significantly for BAC and CAC, whereas glucose concentrations were unchanged. Histology revealed disintegration of the corneal structures for both compounds. Conclusions: The data underline the EVEIT as a predictive toxicity test to show side effects in a time-compressed manner. The consistency of these predictions was previously demonstrated by the EVEIT for BAC, phosphate buffer, and others. The EVEIT is suited for a chronic application prediction of tolerability and toxic side effects of eye drops in particular, and other chemicals in general.


Assuntos
Compostos de Benzalcônio/toxicidade , Córnea/efeitos dos fármacos , Álcoois Graxos/toxicidade , Lubrificantes Oftálmicos/toxicidade , Compostos de Amônio Quaternário/toxicidade , Animais , Compostos de Benzalcônio/administração & dosagem , Cátions/administração & dosagem , Cátions/toxicidade , Córnea/patologia , Álcoois Graxos/administração & dosagem , Lubrificantes Oftálmicos/administração & dosagem , Conservantes Farmacêuticos/administração & dosagem , Conservantes Farmacêuticos/toxicidade , Compostos de Amônio Quaternário/administração & dosagem , Coelhos , Fatores de Tempo , Técnicas de Cultura de Tecidos , Testes de Toxicidade
16.
J Glaucoma ; 29(11): 1006-1016, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-32947358

RESUMO

PURPOSE: To quantify aerosol and droplets generated during noncontact tonometry (NCT) and assess the spread distance of the same. METHODOLOGY: This was an experimental study on healthy human volunteers (n=8 eyes). In an experimental setup, NCT was performed on eyes (n=8) of human volunteers under normal settings, with a single and 2 drops of lubricant. High-speed shadowgraphy, frontal lighting technique, and fluorescein analysis were used to detect the possible generation of any droplets and aerosols. Mathematical computation of the spread of the droplets was then performed. RESULTS: In a natural setting, there was no droplet or aerosol production. Minimal splatter along with droplet ejection was observed when 1 drop of lubricant was used before NCT. When 2 drops of lubricant were instilled, a significant amount of fluid ejection in the form of a sheet that broke up into multiple droplets was observed. Some of these droplets traversed back to the tonometer. Droplets ranging from 100 to 500 µm in diameter were measured. CONCLUSIONS: There was no droplet generation during NCT performed in a natural setting. However, NCT should be avoided in conditions with high-tear volume (natural or artificial) as it would lead to droplet spread and tactile contamination.


Assuntos
Aerossóis/química , Betacoronavirus , Infecções por Coronavirus/transmissão , Transmissão de Doença Infecciosa do Paciente para o Profissional/prevenção & controle , Pressão Intraocular/fisiologia , Pneumonia Viral/transmissão , Lágrimas/química , Tonometria Ocular/instrumentação , Adolescente , Adulto , COVID-19 , Monitoramento Ambiental , Feminino , Fluoresceína/administração & dosagem , Corantes Fluorescentes/administração & dosagem , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Imagem Óptica , Pandemias , SARS-CoV-2 , Adulto Jovem
17.
J Ocul Pharmacol Ther ; 36(8): 602-608, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32701012

RESUMO

Purpose: To compare, in a masked manner, a novel cross-linked hyaluronic acid ocular bandage gel (OBG) versus standard-of-care bandage contact lens (BCL) plus artificial tears with respect to safety and effectiveness in healing epithelial defects created for photorefractive keratectomy (PRK). Methods: This was a randomized, reading center-masked, exploratory study. Forty-five patients (myopic without significant anisometropia) scheduled for bilateral PRK (9-mm epithelial defect) were randomized post-PRK to treatment with OBG 8 times daily for 3 days, followed by 4 times daily for 11 days (Group 1); OBG 4 times daily for 14 days (Group 2); or BCL and artificial tears (Control). A masked reading center used image analysis of digital slit lamp photos of the fluorescein-stained cornea to evaluate defect size during the 14-day postoperative follow-up period. Effectiveness endpoints were (1) time to complete closure of the corneal defect and (2) proportion of patients with complete healing on day 3 postoperatively, whose defect remained closed. Safety assessments included findings for adverse events and vision, Standard Patient Evaluation of Eye Dryness (SPEED™) Questionnaire, slit lamp, intraocular pressure, and fundus examinations. Results: The proportion of patients with complete healing at 3 days was 73.3%, 86.7%, and 66.7% of patients in Groups 1, 2, and Control, respectively. On day 2, the mean wound size was 6%-26% smaller in Groups 1 and 2 compared with Control. No safety concern arose. SPEED scores were not significantly different across groups. Conclusion: OBG offers a well-tolerated and effective therapy for quickly reepithelializing the cornea following trauma, disease, or surgery.


Assuntos
Adjuvantes Imunológicos/farmacologia , Bandagens/efeitos adversos , Ácido Hialurônico/farmacologia , Miopia/cirurgia , Ceratectomia Fotorrefrativa/métodos , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/efeitos adversos , Adulto , Bandagens/estatística & dados numéricos , Estudos de Casos e Controles , Lentes de Contato/efeitos adversos , Córnea/diagnóstico por imagem , Córnea/patologia , Feminino , Fluoresceína/metabolismo , Humanos , Ácido Hialurônico/administração & dosagem , Ácido Hialurônico/efeitos adversos , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Pessoa de Meia-Idade , Cuidados Pós-Operatórios/estatística & dados numéricos , Estudos Prospectivos , Reepitelização/efeitos dos fármacos , Segurança , Lâmpada de Fenda , Resultado do Tratamento , Acuidade Visual/efeitos dos fármacos , Cicatrização/fisiologia
19.
Mol Vis ; 26: 359-369, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32476816

RESUMO

Purpose: To explore the correlation of tear and conjunctival cytokines and sensory hypersensitivity in mild dry eye (MDE) patients characterized by symptoms outweighing signs (DESOS). Methods: The subjects comprised 39 patients with MDE characterized by DESOS, 18 patients with common MDE (CMDE), and 15 healthy controls. The patients with DESOS were randomly subdivided into two groups; the C-DESOS group received artificial tears only, and the G-DESOS group received artificial tears and 0.1% fluorometholone eye drops three times a day. Symptoms were assessed using the Ocular Surface Disease Index (OSDI) and the Neuropathic Pain Symptoms Inventory modified for Eye (NPSI-E) questionnaire. Ocular examinations and in vivo confocal microscopy (IVCM) were also employed. Tear and conjunctival cytokines were measured using Multiplex or RT-PCR on Days 0, 7, and 30. The correlation between the expression of cytokines and hypersensitivity status was analyzed. Results: Compared with the CMDE and control groups, the DESOS groups showed a significant increase in symptom scores and in the ratio of symptoms versus signs. IL-1 ß, IL-2, IL-6, and TNF-α in tears and conjunctiva increased in the DESOS groups compared to the CMDE and control groups, indicating a high correlation with hypersensitivity status in the DESOS groups. Glucocorticoid treatment significantly decreased the level of cytokines in tears and conjunctiva in the G-DESOS group and subsequently ameliorated the symptoms. Conclusions: Tear and conjunctival cytokines, including IL-1 ß, IL-2, IL-6, and TNF-α, were correlated with sensory hypersensitivity status in the DESOS groups, suggesting they play an important role in the discordance of symptoms outweighing signs.


Assuntos
Túnica Conjuntiva/metabolismo , Citocinas/metabolismo , Síndromes do Olho Seco/metabolismo , Lágrimas/metabolismo , Adulto , Citocinas/genética , Síndromes do Olho Seco/diagnóstico por imagem , Síndromes do Olho Seco/tratamento farmacológico , Feminino , Glucocorticoides/farmacologia , Humanos , Hipersensibilidade/tratamento farmacológico , Hipersensibilidade/genética , Hipersensibilidade/metabolismo , Interleucina-1beta/genética , Interleucina-1beta/metabolismo , Interleucina-2/genética , Interleucina-2/metabolismo , Interleucina-6/genética , Interleucina-6/metabolismo , Lubrificantes Oftálmicos/administração & dosagem , Masculino , Microscopia Confocal , Pessoa de Meia-Idade , Inquéritos e Questionários , Lágrimas/efeitos dos fármacos , Fator de Necrose Tumoral alfa/genética , Fator de Necrose Tumoral alfa/metabolismo
20.
J Ocul Pharmacol Ther ; 36(6): 355-365, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32493105

RESUMO

Dry eye disease (DED) is a complex multifactorial disease that affects an increasing number of patients worldwide. Close to 30% of the population has experienced dry eye (DE) symptoms and presented with some signs of the disease during their lifetime. The significant heterogeneity in the medical background of patients with DEs and in their sensitivity to symptoms renders a clear understanding of DED complicated. It has become evident over the past few years that DED results from an impairment of the ocular surface homeostasis. Hence, a holistic treatment approach that concomitantly addresses the different mechanisms that result in the destabilization of the tear film (TF) and the ocular surface would be appropriate. The goal of the present review is to compile the different types of scientific evidence (from in silico modeling to clinical trials) that help explain the mechanism of action of cationic emulsion (CE)-based eye drop technology for the treatment of both the signs and the symptoms of DED. These CE-based artificial tear (AT) eye drops designed to mimic, from a functional point of view, a healthy TF contribute to the restoration of a healthy ocular surface environment and TF that leads to a better management of DE patients. The CE-based AT eye drops help restore the ocular surface homeostasis in patients who have unstable TF or no tears.


Assuntos
Síndromes do Olho Seco/tratamento farmacológico , Emulsões/química , Lubrificantes Oftálmicos/uso terapêutico , Fenômenos Fisiológicos Oculares/efeitos dos fármacos , Adulto , Emulsões/farmacologia , Voluntários Saudáveis/estatística & dados numéricos , Homeostase , Humanos , Lubrificantes Oftálmicos/administração & dosagem , Lubrificantes Oftálmicos/química , Propriedades de Superfície/efeitos dos fármacos , Lágrimas/fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...